X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10412) 10412
Book Review (3195) 3195
Publication (545) 545
Newsletter (469) 469
Newspaper Article (357) 357
Book Chapter (70) 70
Magazine Article (38) 38
Book / eBook (31) 31
Conference Proceeding (24) 24
Trade Publication Article (15) 15
Transcript (8) 8
Reference (4) 4
Dissertation (3) 3
Report (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8410) 8410
humans (7563) 7563
anticoagulants (5602) 5602
male (3347) 3347
female (2982) 2982
anticoagulants - therapeutic use (2906) 2906
warfarin (2688) 2688
anticoagulants - administration & dosage (2566) 2566
pharmacology & pharmacy (2260) 2260
anticoagulants - adverse effects (2026) 2026
aged (1973) 1973
hematology (1930) 1930
middle aged (1927) 1927
anticoagulants - pharmacokinetics (1852) 1852
pharmacokinetics (1584) 1584
animals (1555) 1555
adult (1523) 1523
peripheral vascular disease (1464) 1464
administration, oral (1447) 1447
anticoagulants - pharmacology (1413) 1413
thromboembolism (1398) 1398
venous thromboembolism (1360) 1360
thrombosis (1314) 1314
rivaroxaban (1286) 1286
atrial fibrillation (1260) 1260
dabigatran (1232) 1232
prevention (1209) 1209
heparin (1195) 1195
risk factors (1167) 1167
drug therapy (1133) 1133
anticoagulation (1123) 1123
stroke (1123) 1123
cardiac & cardiovascular systems (1044) 1044
molecular-weight heparin (993) 993
treatment outcome (992) 992
hemorrhage - chemically induced (988) 988
thrombin (988) 988
abridged index medicus (986) 986
dose-response relationship, drug (986) 986
analysis (974) 974
research (953) 953
drug interactions (946) 946
blood coagulation - drug effects (909) 909
medicine & public health (908) 908
therapy (878) 878
aged, 80 and over (858) 858
care and treatment (841) 841
warfarin - administration & dosage (814) 814
international normalized ratio (810) 810
factor xa inhibitors (796) 796
atrial-fibrillation (761) 761
dosage and administration (737) 737
warfarin - therapeutic use (732) 732
health aspects (721) 721
pharmacodynamics (719) 719
apixaban (713) 713
atrial fibrillation - drug therapy (708) 708
enoxaparin (702) 702
unfractionated heparin (697) 697
anticoagulant (679) 679
surgery (676) 676
warfarin - pharmacokinetics (673) 673
patients (657) 657
medicine, general & internal (655) 655
risk (640) 640
cardiology (636) 636
deep-vein thrombosis (634) 634
management (610) 610
warfarin - adverse effects (601) 601
pharmacology (597) 597
safety (595) 595
stroke - prevention & control (582) 582
bleeding (576) 576
coagulation (566) 566
oral anticoagulants (564) 564
drug dosages (555) 555
thromboembolism - prevention & control (551) 551
clinical trials (547) 547
rats (539) 539
internal medicine (536) 536
retrospective studies (522) 522
dabigatran etexilate (521) 521
time factors (520) 520
heparin - therapeutic use (505) 505
medical research (504) 504
cardiac arrhythmia (503) 503
drugs (497) 497
hemorrhage (494) 494
atrial fibrillation - complications (488) 488
heparin, low-molecular-weight - therapeutic use (484) 484
glycosaminoglycans (461) 461
usage (451) 451
pharmacology/toxicology (446) 446
antithrombotic therapy (442) 442
factor xa inhibitor (436) 436
partial thromboplastin time (436) 436
pharmacogenetics (432) 432
direct thrombin inhibitor (431) 431
blood (427) 427
mortality (424) 424
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11014) 11014
German (115) 115
French (76) 76
Russian (39) 39
Spanish (35) 35
Japanese (23) 23
Italian (21) 21
Chinese (10) 10
Czech (10) 10
Danish (7) 7
Polish (7) 7
Swedish (6) 6
Dutch (5) 5
Hungarian (4) 4
Korean (4) 4
Portuguese (4) 4
Turkish (4) 4
Bulgarian (2) 2
Finnish (2) 2
Serbian (2) 2
Romanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacokinetics, ISSN 0312-5963, 2008, Volume 47, Issue 3, pp. 203 - 216
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2016, Volume 60, Issue 1, pp. 105 - 114
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2008, Volume 47, Issue 1, pp. 47 - 59
Objectives: To investigate the pharmacokinetic and pharmacodynamic profile of dabigatran in healthy elderly subjects; to assess the intra- and interindividual... 
Dabigatran etexilate | Thrombin inhibitors | Elderly | Research and development | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Dabigatran etexilate, pharmacokinetics | Thrombin inhibitors, pharmacokinetics | REPLACEMENT | APTT | MANAGEMENT | THERAPY | VENOUS THROMBOEMBOLISM | TOTAL HIP | DISEASE | ETEXILATE | PHARMACOLOGY & PHARMACY | Anticoagulants - administration & dosage | Area Under Curve | Humans | Thrombin - antagonists & inhibitors | Pyridines - pharmacokinetics | Biological Availability | Male | Dabigatran | Flatulence - chemically induced | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Diarrhea - chemically induced | Tandem Mass Spectrometry | Hematoma - chemically induced | Capsules | Benzimidazoles - administration & dosage | Aged, 80 and over | Chromatography, Liquid | Anti-Ulcer Agents - pharmacology | Female | Benzimidazoles - blood | Pyridines - administration & dosage | Administration, Oral | Benzimidazoles - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Anticoagulants - blood | Pyridines - blood | Blood Coagulation - drug effects | Partial Thromboplastin Time | Sex Factors | Aged | Anticoagulants - pharmacokinetics | Metabolic Clearance Rate - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Index Medicus
Journal Article
Journal Article
Journal Article
Regulatory Toxicology and Pharmacology, ISSN 0273-2300, 02/2011, Volume 59, Issue 1, pp. 176 - 183
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
AimsThe anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
cytochrome | glycoprotein | rivaroxaban | drug interactions | healthy subjects | 450 | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | cytochrome P450 | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism | Index Medicus
Journal Article
Advances in Therapy, ISSN 0741-238X, 2/2012, Volume 29, Issue 2, pp. 163 - 177
Coronary heart disease, stroke, and peripheral vascular disease are the most common causes of mortality in patients with type 2 diabetes mellitus (T2DM). The... 
dapagliflozin | pharmacodynamics | Rheumatology | simvastatin | sodium glucose co-transporter-2 | Internal Medicine | Oncology | digoxin | warfarin | type 2 diabetes | Medicine & Public Health | pharmacokinetics | valsartan | Cardiology | Pharmacology/Toxicology | Endocrinology | MEDICINE, RESEARCH & EXPERIMENTAL | SELECTIVE SGLT2 INHIBITOR | HEALTHY-SUBJECTS | HUMANS | INADEQUATE GLYCEMIC CONTROL | DIABETES-MELLITUS | POTENT | HYPERGLYCEMIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TYPE-2 | ASSOCIATION | Hypoglycemic Agents - pharmacokinetics | Benzhydryl Compounds | Valsartan | Valine - pharmacokinetics | Humans | Middle Aged | Valine - analogs & derivatives | Male | Glucosides - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Simvastatin - pharmacokinetics | Anti-Arrhythmia Agents - pharmacokinetics | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Cross-Over Studies | Anticholesteremic Agents - pharmacokinetics | Drug Interactions | Adult | Female | Anticoagulants - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Tetrazoles - pharmacokinetics | Type 2 diabetes | Warfarin | Digoxin | Simvastatin | Drug interactions | Anticoagulants (Medicine) | Glucose | Dextrose | Antilipemic agents | Cardiac glycosides | Blood circulation disorders | Cardiotonic agents | Cardiac patients | Diabetes | Heart diseases | Health technology assessment
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 11/2014, Volume 70, Issue 11, pp. 1339 - 1351
Journal Article